Published in Clin Cancer Res on June 24, 2011
Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol (2014) 3.47
Gene expression profiling of the leading edge of cutaneous squamous cell carcinoma: IL-24-driven MMP-7. J Invest Dermatol (2013) 1.50
Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology (2013) 1.47
Interferon-γ Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice. PLoS Pathog (2015) 1.41
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer (2015) 1.32
Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology (2015) 1.16
Targeting caspases in cancer therapeutics. Biol Chem (2013) 1.13
Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc Natl Acad Sci U S A (2014) 1.01
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function. Autophagy (2013) 0.97
Long Non-Coding RNA BST2/BISPR is Induced by IFN and Regulates the Expression of the Antiviral Factor Tetherin. Front Immunol (2015) 0.96
Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS One (2013) 0.96
CD271 on melanoma cell is an IFN-γ-inducible immunosuppressive factor that mediates downregulation of melanoma antigens. J Invest Dermatol (2013) 0.95
Immunomodulatory effects of interferons in malignancies. J Interferon Cytokine Res (2013) 0.95
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics (2015) 0.94
Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies. Mediators Inflamm (2015) 0.93
High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines. Assay Drug Dev Technol (2013) 0.91
IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol (2013) 0.91
Different STAT Transcription Complexes Drive Early and Delayed Responses to Type I IFNs. J Immunol (2015) 0.91
New PARP targets for cancer therapy. Nat Rev Cancer (2014) 0.91
Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol (2016) 0.91
Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors. Clin Cancer Res (2014) 0.90
Type II interferon promotes differentiation of myeloid-biased hematopoietic stem cells. Stem Cells (2014) 0.88
Development and characterization of a reliable mouse model of colorectal cancer metastasis to the liver. Clin Exp Metastasis (2013) 0.88
Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol (2016) 0.84
Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A (2016) 0.83
LBH589 enhances T cell activation in vivo and accelerates graft-versus-host disease in mice. Biol Blood Marrow Transplant (2012) 0.83
Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol (2014) 0.83
Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling. Immunol Cell Biol (2016) 0.83
Secretion of interferon gamma from human immune cells is altered by exposure to tributyltin and dibutyltin. Environ Toxicol (2013) 0.83
ADAM17 silencing in mouse colon carcinoma cells: the effect on tumoricidal cytokines and angiogenesis. PLoS One (2012) 0.83
Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals. Eur J Immunol (2015) 0.82
T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN-γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. Cell Rep (2015) 0.82
Adenovirus-mediated delivery of interferon-γ gene inhibits the growth of nasopharyngeal carcinoma. J Transl Med (2012) 0.82
Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes. Sci Rep (2013) 0.82
Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS One (2013) 0.82
Downregulation of IFNG in CD4(+) T cells in lung cancer through hypermethylation: a possible mechanism of tumor-induced immunosuppression. PLoS One (2013) 0.82
Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunol Res (2016) 0.82
Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner. Oncotarget (2015) 0.81
Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect. Immunology (2014) 0.81
Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity. Mol Ther Oncolytics (2016) 0.80
Methylation patterns of the IFN-γ gene in cervical cancer tissues. Sci Rep (2014) 0.79
Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells. Immunology (2014) 0.79
Curcuminoids and ω-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon γ production. Front Physiol (2015) 0.79
Mapping and Identification of the Urine Proteome of Prostate Cancer Patients by 2D PAGE/MS. Int J Proteomics (2014) 0.79
A novel mechanism of skin tumor promotion involving interferon-gamma (IFNγ)/signal transducer and activator of transcription-1 (Stat1) signaling. Mol Carcinog (2014) 0.79
Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions. J Interferon Cytokine Res (2016) 0.79
Synergistic COX2 Induction by IFNγ and TNFα Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. Cancer Immunol Res (2016) 0.78
Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol (2015) 0.78
Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations. Cancer Immunol Res (2015) 0.78
Shedding light on melanocyte pathobiology in vivo. Cancer Res (2012) 0.78
In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice. Drug Des Devel Ther (2015) 0.78
Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells. Cancer Sci (2016) 0.78
Inhibition of NF-κB in Tumor Cells Exacerbates Immune Cell Activation Following Photodynamic Therapy. Int J Mol Sci (2015) 0.78
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov (2016) 0.77
Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells. Biochim Biophys Acta (2016) 0.77
Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts. Biomedicines (2016) 0.77
Hexabromocyclododecane and tetrabromobisphenol A alter secretion of interferon gamma (IFN-γ) from human immune cells. Arch Toxicol (2015) 0.76
Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer. Oncotarget (2016) 0.76
Attenuated mutant strain of Salmonella Typhimurium lacking the ZnuABC transporter contrasts tumor growth promoting anti-cancer immune response. Oncotarget (2015) 0.76
Single nucleotide polymorphisms in the interferon gamma gene are associated with distinct types of retinochoroidal scar lesions presumably caused by Toxoplasma gondii infection. Mem Inst Oswaldo Cruz (2014) 0.76
Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget (2017) 0.75
Autophagy mediated by arginine depletion activation of the nutrient sensor GCN2 contributes to interferon-γ-induced malignant transformation of primary bovine mammary epithelial cells. Cell Death Discov (2016) 0.75
Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer (2017) 0.75
Interferon-γ polymorphism and hepatocellular carcinoma susceptibility: a meta analysis. Int J Clin Exp Med (2015) 0.75
Pharmacokinetic studies of the recombinant chicken interferon-α in broiler chickens. J Vet Med Sci (2016) 0.75
Conservation of immune gene signatures in solid tumors and prognostic implications. BMC Cancer (2016) 0.75
Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model. Cell Death Dis (2016) 0.75
Association of Interferon Gamma +874T/A Polymorphism and Leukemia Risk: A Meta-Analysis. Medicine (Baltimore) (2016) 0.75
Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses. ILAR J (2016) 0.75
Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets. Biomicrofluidics (2016) 0.75
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy. Oncolytic Virother (2015) 0.75
Disabling of the erbB Pathway Followed by IFN-γ Modifies Phenotype and Enhances Genotoxic Eradication of Breast Tumors. Cell Rep (2015) 0.75
PEGylation improves the pharmacokinetic properties and ability of interferon gamma to inhibit growth of a human tumor xenograft in athymic mice. J Interferon Cytokine Res (2014) 0.75
Rapid Detection of Neutrophil Oxidative Burst Capacity is Predictive of Whole Blood Cytokine Responses. PLoS One (2015) 0.75
Identification of immunomodulatory signatures induced by american ginseng in murine immune cells. Evid Based Complement Alternat Med (2013) 0.75
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting. Nat Commun (2017) 0.75
Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation. Oncoimmunology (2016) 0.75
Novel function of STAT1 in breast cancer. Oncoimmunology (2013) 0.75
The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression. Vaccines (Basel) (2016) 0.75
Diet-driven interferon-γ enhances malignant transformation of primary bovine mammary epithelial cells through nutrient sensor GCN2-activated autophagy. Cell Death Dis (2016) 0.75
TLR4-mediated immunomodulatory properties of the bacterial metalloprotease arazyme in preclinical tumor models. Oncoimmunology (2016) 0.75
Interleukin-12 bypasses common gamma-chain signalling in emergency natural killer cell lymphopoiesis. Nat Commun (2016) 0.75
Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget (2016) 0.75
Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells. Oncotarget (2016) 0.75
Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies. NPJ Syst Biol Appl (2017) 0.75
PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol (2017) 0.75
Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells. PLoS One (2017) 0.75
Sustained mitogenic effect on K562 human chronic myelogenous leukemia cells by dietary lectin, jacalin. Glycoconj J (2016) 0.75
Cell type-dependent regulation of free ISG15 levels and ISGylation. J Cell Commun Signal (2017) 0.75
The role of dendritic cells in cancer. Semin Immunopathol (2016) 0.75
Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer. Inflammopharmacology (2016) 0.75
MYC Modulation around the CDK2/p27/SKP2 Axis. Genes (Basel) (2017) 0.75
Systemic cytokine and chemokine responses in immunized mice challenged with staphylococcal enterotoxin B. Toxicon (2017) 0.75
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34
Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell (1995) 10.16
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
The three Es of cancer immunoediting. Annu Rev Immunol (2004) 8.20
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Interferons, interferon-like cytokines, and their receptors. Immunol Rev (2004) 6.21
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
Type I interferon: friend or foe? J Exp Med (2010) 4.40
SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell (1999) 4.29
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science (1996) 3.70
Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol (2002) 3.64
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity (2009) 3.51
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell (1998) 3.25
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell (1999) 3.15
Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J Clin Immunol (2003) 2.93
High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol (1997) 2.59
Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol (2008) 2.59
Phosphorylation of the Stat1 transactivation domain is required for full-fledged IFN-gamma-dependent innate immunity. Immunity (2003) 2.51
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev (2008) 2.47
Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med (1998) 2.42
Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev (2006) 2.10
Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity (2000) 2.10
Structural bases of unphosphorylated STAT1 association and receptor binding. Mol Cell (2005) 2.05
A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev (2009) 1.98
Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene (2008) 1.97
Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev (2008) 1.96
Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2001) 1.96
Three-dimensional structure of recombinant human interferon-gamma. Science (1991) 1.88
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol (2007) 1.74
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
Clinical Use of Interferon-gamma. Ann N Y Acad Sci (2009) 1.69
Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci U S A (2005) 1.68
Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol (1999) 1.68
Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst (1995) 1.67
Exacerbation of antigen-induced arthritis in IFN-gamma-deficient mice as a result of unrestricted IL-17 response. J Immunol (2007) 1.58
IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol (2000) 1.56
Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes Dev (2006) 1.53
Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol (2006) 1.50
Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity (1998) 1.49
Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci U S A (2008) 1.45
Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol (2001) 1.39
Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer (1988) 1.33
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood (2010) 1.26
Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res (1999) 1.26
IFN-gamma-dependent inhibition of tumor angiogenesis by tumor-infiltrating CD4+ T cells requires tumor responsiveness to IFN-gamma. J Immunol (2001) 1.24
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest (1991) 1.21
Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer (1993) 1.15
The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci (1999) 1.15
A linear signal transduction pathway involving phosphatidylinositol 3-kinase, protein kinase Cepsilon, and MAPK in mesangial cells regulates interferon-gamma-induced STAT1alpha transcriptional activation. J Biol Chem (2004) 1.13
Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res (1988) 1.12
The interferon (IFN)-induced GTPase, mGBP-2. Role in IFN-gamma-induced murine fibroblast proliferation. J Biol Chem (2001) 1.09
Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci U S A (1987) 1.03
Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol (1990) 1.02
The role of TNF in cancer. Results Probl Cell Differ (2009) 1.01
Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol (2001) 1.01
Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol (2000) 0.99
Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin Cancer Biol (2007) 0.98
Recombinant gamma-interferon induces changes in expression and shedding of antigens associated with normal human melanocytes, nevus cells, and primary and metastatic melanoma cells. J Immunol (1985) 0.98
Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol (1987) 0.97
Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol (2004) 0.95
IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res (2008) 0.94
MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol (2011) 0.94
Natural killer susceptibility is independent of HLA class I antigen expression on cell lines obtained from human solid tumors. Eur J Immunol (1990) 0.93
IFN-gamma induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res (1999) 0.90
Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma. J Immunother Emphasis Tumor Immunol (1993) 0.89
Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst (1990) 0.87
A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol (1987) 0.83
Phase II study of recombinant interferon-gamma in patients with disseminated malignant melanoma. Cancer Treat Rep (1987) 0.82
CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp Hematol (1999) 0.82
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res (1996) 0.80
Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood (1987) 0.79
Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-beta and recombinant interferon-gamma. Dermatologica (1990) 0.79
Measurement of the effect of interferons on cellular differentiation in murine and human melanoma cells. Methods Enzymol (1986) 0.79
A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemia. Eur J Haematol (1992) 0.77
Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature (2011) 3.56
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med (2004) 2.90
Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med (2002) 2.58
Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF. PLoS One (2009) 2.03
Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal (2011) 1.90
Melanoma induction by ultraviolet A but not ultraviolet B radiation requires melanin pigment. Nat Commun (2012) 1.90
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J Clin Invest (2009) 1.83
A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A (2007) 1.61
Ultraviolet B but not ultraviolet A radiation initiates melanoma. Cancer Res (2004) 1.57
Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatr Blood Cancer (2011) 1.53
The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res (2006) 1.52
MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One (2009) 1.40
Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene (2002) 1.40
MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest (2009) 1.38
Modeling metastasis biology and therapy in real time in the mouse lung. J Clin Invest (2010) 1.32
Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol (2002) 1.28
Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis. Cancer Res (2002) 1.24
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res (2007) 1.22
Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39. Am J Hum Genet (2009) 1.21
Ultraviolet radiation and cutaneous malignant melanoma. Oncogene (2003) 1.17
Progress in cutaneous cancer research. J Investig Dermatol Symp Proc (2002) 1.16
Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res (2002) 1.14
Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res (2003) 1.13
Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study. Pigment Cell Melanoma Res (2009) 1.12
Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene (2002) 1.06
VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest (2005) 1.04
Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03
Genetic instability favoring transversions associated with ErbB2-induced mammary tumorigenesis. Proc Natl Acad Sci U S A (2002) 0.99
From UVs to metastases: modeling melanoma initiation and progression in the mouse. J Invest Dermatol (2008) 0.97
Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events. Pigment Cell Res (2003) 0.97
Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle (2008) 0.97
Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation. Am J Pathol (2006) 0.91
Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One (2010) 0.91
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin. Int J Cancer (2011) 0.91
p53 loss increases the osteogenic differentiation of bone marrow stromal cells. Stem Cells (2015) 0.83
In vivo role of alternative splicing and serine phosphorylation of the microphthalmia-associated transcription factor. Genetics (2012) 0.83
Building the perfect beast: complex mouse models teach surprisingly simple melanoma lessons. Pigment Cell Melanoma Res (2009) 0.82
A traitor in our midst: mesenchymal stem cells contribute to tumor progression and metastasis. Future Oncol (2008) 0.82
NM23 deficiency promotes metastasis in a UV radiation-induced mouse model of human melanoma. Clin Exp Metastasis (2012) 0.81
Selenium and selenoprotein deficiencies induce widespread pyogranuloma formation in mice, while high levels of dietary selenium decrease liver tumor size driven by TGFα. PLoS One (2013) 0.81
A genetically engineered mouse model with inducible GFP expression in melanocytes. Pigment Cell Melanoma Res (2011) 0.81
Sunscreen prevention of melanoma in man and mouse. Pigment Cell Melanoma Res (2010) 0.81
Overexpression of NK2 inhibits liver regeneration after partial hepatectomy in mice. World J Gastroenterol (2005) 0.80
TGFbeta1 and TGFalpha contrarily affect alveolar survival and tumorigenesis in mouse mammary epithelium. Int J Cancer (2007) 0.79
Meeting report: fourth international congress of the Society for Melanoma Research. Pigment Cell Melanoma Res (2008) 0.79
Imaging melanoma in a murine model using reflectance-mode confocal scanning laser microscopy and polarized light imaging. J Investig Dermatol Symp Proc (2005) 0.78
Noninvasive imaging of melanoma with reflectance mode confocal scanning laser microscopy in a murine model. J Invest Dermatol (2007) 0.78
Shedding light on melanocyte pathobiology in vivo. Cancer Res (2012) 0.78
Illuminating progression: tracking melanoma metastasis in a gene therapy setting. Pigment Cell Melanoma Res (2011) 0.77
Animal models of melanoma. J Investig Dermatol Symp Proc (2005) 0.76
Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer. Clin Cancer Res (2011) 0.76
Roles for aberrant CXCR3 signaling in basal cell carcinoma: a case for dual activity. Am J Pathol (2010) 0.76
The ARFul truth about melanoma susceptibility genes. Pigment Cell Melanoma Res (2007) 0.76
Fluorescent protein-assisted purification for gene expression profiling. Methods Mol Biol (2011) 0.76
Chemoprevention of melanoma. Curr Oncol Rep (2004) 0.75
β-catenin in metastatic melanoma--the smoking gun reloaded. Pigment Cell Melanoma Res (2012) 0.75
Cancer biology: the weakest link? Nature (2005) 0.75
A melanin-independent interaction between Mc1r and Met signaling pathways is required for HGF-dependent melanoma. Int J Cancer (2014) 0.75
Lymphangiogenesis: From passive disseminator to dynamic metastatic enabler. Pigment Cell Melanoma Res (2017) 0.75
Flipping the phenotypic switch on a novel antimelanoma differentiation strategy. Pigment Cell Melanoma Res (2013) 0.75
Unraveling the melanoma pathogenome. Pigment Cell Melanoma Res (2012) 0.75